Strategies for pneumococcal vaccination in older adults in the coming era.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

1. Preventive Strategies and Determinants of Vaccination Compliance Among Older Adults in Rural Amazonian Communities.Vaccines · 2026
   Article
2. Risk factors for community-acquired pneumonia in older adults in Japan after the introduction of the childhood PCV13.BMC infectious diseases · 2026
   Article
3. Assessing the Lower Incidence of Invasive Pneumococcal Diseases in Japan During the COVOD-19 Pandemic.International journal of general medicine · 2026
   Article
4. Real world effectiveness of antipneumococcal vaccination against pneumonia in adults: a population-based cohort study, Catalonia, 2019.BMC infectious diseases · 2025
   Article
5. Trends in the global burden of childhood meningitis between 1990 and 2021 and projections to 2035: based on the global burden of diseases database 2021.BMC public health · 2025
   Article
6. [Recommendations on prevention and treatment of respiratory infections in institutionalised older people].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
   Review
7. Pneumococcal Vaccination Rates Among Patients Hospitalized for Pneumococcal Infection at a Community Teaching Hospital.Cureus · 2025
   Article
8. Novel processes to obtain pneumococcal surface proteins for vaccines.Applied microbiology and biotechnology · 2025
   Review
9. A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).Vaccines · 2025
   Article
10. Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review.Healthcare (Basel, Switzerland) · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as